Ondrej Kalita

Dr. Ondrej Kalita

Neurosurgery, Palacký University, Olomouc, Olomoucký Kraj, Czech Republic
orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 August 2008 in Cell Cycle
Verified
Journal Article
Closed access
PKPetra Knizetova
Petra Knizetova
JEJiri Ehrmann
Jiri Ehrmann
AHAlice Hlobilkova
Alice Hlobilkova
IVIveta Vancova
Iveta Vancova
OKOndrej Kalita
Ondrej Kalita
JBJiri Bartek
Jiri Bartek
Vascular endothelial growth factor (VEGF) plays a crucial role in angiogenesis and progression of malignant brain tumors. Given the significance of tumor microenvironment in general, and the establ...

11 January 2013 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
VBVladimir Balik
Vladimir Balik
JSJosef Srovnal
Josef Srovnal
ISIgor Sulla
Igor Sulla
OKOndrej Kalita
Ondrej Kalita
TFTatiana Foltanova
Tatiana Foltanova
MHMarian Hajduch
Marian Hajduch

1 January 2009 in Neoplasma
Verified
Journal Article
Closed access
AHA. Hlobilkova
A. Hlobilkova
JEJ. Ehrmann
J. Ehrmann
PKP. Knizetova
P. Knizetova
VKV. Krejci
V. Krejci
OKOndrej Kalita
Ondrej Kalita
ZKZ. Kolar
Z. Kolar
Analysis of VEGF, Flt-1, Flk-1, nestin and MMP-9 in relation to astrocytoma pathogenesis and progression.

3 December 2021 in Applied Immunohistochemistry & Molecular Morphology
Verified
Journal Article
Open access
ZŠZuzana Šporiková
Zuzana Šporiková
RSRastislav Slavkovsky
Rastislav Slavkovsky
LTLucie Tuckova
Lucie Tuckova
OKOndrej Kalita
Ondrej Kalita
MHMagdalena Megova Houdova
Magdalena Megova Houdova
MVMiroslav Vaverka
Miroslav Vaverka
Patients below 55 years were genetically studied because the prevalence of isocitrate dehydrogenase 1 (IDH1) decreases in older patients and on grounds of cost-effectiveness, as suggested by the World Health Organization (WHO) in 2016. The aim of our study was to use novel massively parallel sequencing (MPS) approaches to examine rare variants of IDH1/2 in Czech diffuse astrocytic and oligodendroglial tumors (gliomas) patients below 55 years of age who had been immunohistochemically (IHC) diagnosed as IDH1 R132H negative. The IHC IDH1 status (wild type or mutant) of 275 tissue samples was analyzed using antibodies against the IDH1 R132H protein. Sixty-three samples of 55 years old patients with IHC IDH1 WT status were genotyped using two different MPS technologies to detect rare IDH1 and IDH2 variants. The tiered IHC (60 positive) and molecular (10 positive) approach thus revealed that 70 of the 275 samples (25%) bore IDH1/IDH2 mutations. The combined molecular and IHC approach thus revealed that 70 of the 275 samples (25%) considered in the study bore IDH1/IDH2 mutations. IHC detection of the IDH1 R132H variant should be routinely complemented with MPS to detect rare IDH1/2 variants in glioma patients below 55 years of age with negative IHC result of IDH R132H variant.

26 May 2011 in International Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
OKOndrej Kalita
Ondrej Kalita
Intramedullary spinal cord metastasis (ISCM) is the rarest type of CNS involvement by systemic malignant tumours. Optimal management of patients with ISCMs remains ambiguous. Based on two cases reported from our department, we focused on the strategy for intramedullary spinal cord metastases surgery.

3 December 2008 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
LHLumír Hrabálek
Lumír Hrabálek
OKOndrej Kalita
Ondrej Kalita
HSHana Svebisova
Hana Svebisova
JEJiri Ehrmann
Jiri Ehrmann
MHMarian Hajduch
Marian Hajduch
MKMiroslav Kala
Miroslav Kala